Eliphos label

Eliphos

Eliphos Recall

Get an alert when a recall is issued.

Add Info

Side Effects & Adverse Reactions

Patients with end stage renal failure may develop hypercalcemia when given calcium with meals. No other calcium supplements should be given concurrently with ELIPHOS® .

Progressive hypercalcemia due to overdose of ELIPHOS® may be severe as to require emergency measures. Chronic hypercalcemia may lead to vascular calcification, and other soft-tissue calcification. The serum calcium level should be monitored twice weekly during the early dose adjustment period.

The serum calcium times phosphate (CaXP) product should not be allowed to exceed 66. Radiographic evaluation of suspect anatomical region may be helpful in early detection of soft-tissue calcification.

Add Info

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Add Info

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

Add Info

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Add Info

Uses

ELIPHOS® is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption.

Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

Each white, round tablet (stamped “CYP910”) contains 667 mg calcium acetate, USP (anhydrous; Ca(CH3COO)2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, polyethylene glycol 8000 NF; sodium lauryl sulfate, NF; and crospovidone, NF. ELIPHOS® (Calcium Acetate, USP) are administered orally for the control of hyperphosphatemia in end stage renal failure.

Add Info
Add to My Alerts
Report Side Effect
Leave a Review
Navigate to :
Eliphos Recall
Side Effects & Adverse Reactions
Legal Issues
FDA Safety Alerts
Manufacturer Warnings
FDA Labeling Changes
Uses
History
Other Information
Manufacturers
Trending Topics

Eliphos Manufacturers

  • Kaiser Foundation Hospitals
    Eliphos | Kaiser Foundation Hospitals
    No Recall

    Eliphos | Kaiser Foundation Hospitals

    Eliphos | Kaiser Foundation Hospitals

    The recommended initial dose of ELIPHOS® for the adult dialysis patient is 2 tablets with each meal. The dosage may be increased gradually to bring the serum phosphate value below 6 mg/dl, as long as hypercalcemia does not develop. Most patients require 3-4 tablets with each meal.

  • Hawthorn Pharmaceutical, Inc.
    Eliphos | Hawthorn Pharmaceutical, Inc.
    No Recall

    Eliphos | Hawthorn Pharmaceutical, Inc.

    Eliphos | Hawthorn Pharmaceutical, Inc.

    The recommended initial dose of ELIPHOS® for the adult dialysis patient is 2 tablets with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3-4 tablets with each meal.

  • Carilion Materials Management
    Eliphos | Carilion Materials Management
    No Recall

    Eliphos | Carilion Materials Management

    Eliphos | Carilion Materials Management

    The recommended initial dose of ELIPHOS(R) for the adult dialysis patient is 2 tablets with each meal. The dosage may be increased gradually to bring the serum phosphate value below 6 mg/dl, as long as hypercalcemia does not develop. Most patients require 3–4 tablets with each meal. Dosage and Administration:

Login To Your Free Account